NCT03218241View on ClinicalTrials.gov

Single Ascending Dose Study of PRT064445, a Factor Xa (fXa) Inhibitor Antidote

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

September 30, 2012

Study Completion Date

October 31, 2012

Conditions
Healthy
Interventions
BIOLOGICAL

PRT064445

Intravenous

DRUG

Placebo

Intravenous to mimic PRT064445

Trial Locations (1)

85283

Phoenix

Sponsors
All Listed Sponsors
lead

Portola Pharmaceuticals

INDUSTRY

NCT03218241 - Single Ascending Dose Study of PRT064445, a Factor Xa (fXa) Inhibitor Antidote | Biotech Hunter | Biotech Hunter